SHARE:   Share to Facebook Share to Twitter Share to Linked In Share via Email  

Back To Search Results

S10 - "Best Of" Session: MS and CNS Inflammatory Disease

Event Time: Monday April 24, 2017 8:00 am to 9:00 am
Topic(s): MS and CNS Inflammatory Disease
Director(s):
Description: A platform session that brings together the top four scoring abstracts in a particular topic, as rated by the topic reviewers. Offers an opportunity to interact with the author in a smaller setting at the conclusion of the session.
Completion Message:
CME Credits: 1
Core Competencies:

Program Speakers - Tentative

Start/End Time Title Faculty
8:35 AM - 8:45 AM Panel Discussion None  
8:45 AM - 9:00 AM Meet the Investigators None  

Disclosures

Speaker Disclosure

Abstract Presenters

Start Time Pub. Title Presenter
8:00 AM 001 Longitudinal characterization of cortical lesion evolution in multiple sclerosis by ultra high field MRI Constantina A Treaba
Disclosure:
Dr. Treaba has nothing to disclose.

8:08 AM 002 Durable Reduction in MRI Disease Activity With Alemtuzumab in the Absence of Continuous Treatment in Patients With Active Relapsing-Remitting Multiple Sclerosis Who Were Treatment-Naive: 6-Year Follow-up of the CARE-MS I Study Douglas L Arnold, MD
Disclosure:
Dr. Arnold has received personal compensation for activities with Bayer, Biogen, Coronado Biosciences, Consortium of Multiple Sclerosis Centers, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, Merck Serono, MS Forum, NeuroRx Research, Novartis, Opexa Therapeutics, Roche, S.A. Serono Symposia International Foundation, Teva, the Canadian Institutes of Health Research, and the Multiple Sclerosis Society of Canada.

8:16 AM 003 Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited. Shayandokht Taleb, MD
Disclosure:
Dr. Taleb has nothing to disclose.

8:24 AM 004 Self-reported fatigue and lower limb problems predictive of conversion to secondary progressive multiple sclerosis in an aging sample of patients Caila Vaughn
Disclosure:
Dr. Vaughn has nothing to disclose.

Register Now

Related Courses

Saturday April 21, 2018

9:30 AM-11:30 AM
C11 Treatment of Pediatric Multiple Sclerosis in the Current Era Brenda Banwell MD, FAAN

Sunday April 22, 2018

7:00 AM-9:00 AM
C33 Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-Making Aaron Miller MD, FAAN
3:30 PM-5:30 PM
C57 Spanish: Update on MS Therapy Lilyana Amezcua MD

Tuesday April 24, 2018

7:00 AM-9:00 AM
C97 Multiple Sclerosis Overview I: Clinical Pearls John Corboy MD, FAAN
1:00 PM-3:00 PM
C107 Multiple Sclerosis Overview II: Clinical Advances Scott Newsome DO, FAAN
3:30 PM-5:30 PM
C121 Multiple Sclerosis Overview III: Basic and Translational Science Michael Racke MD

Wednesday April 25, 2018

7:00 AM-9:00 AM
C135 Multiple Sclerosis Therapy: Disease-modifying Treatment I David Jones MD
9:15 AM-11:30 AM
PL5 Frontiers in Neuroscience Plenary Session
1:00 PM-3:00 PM
C146 Multiple Sclerosis Therapy: Disease-modifying Treatment II John Rose MD, FAAN
3:30 PM-5:30 PM
C161 Multiple Sclerosis Therapy: Symptom Management Jonathan Carter MD

Thursday April 26, 2018

7:00 AM-9:00 AM
C174 Clinical Pearls in Autoimmune Neurology: Real World Cases Stacey Clardy MD, PhD
1:00 PM-3:00 PM
N5 Neuroscience in the Clinic: Treatment of Progressive Multiple Sclerosis Eric Klawiter MD,
Ellen Mowry MD, FAAN

Friday April 27, 2018

1:00 PM-3:00 PM
C223 Neuromyelitis Optica Spectrum Disorders Dean Wingerchuk MD, FAAN

MEMBER LOG IN

Forgot Password?